MP07-09 12-MONTH ANALYSIS OF ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN: SUSTAINED OXALATE LOWERING AND KIDNEY STONE EVENT RATES IN PRIMARY HYPEROXALURIA TYPE 1
Dean G. Assimos(Twitter (United States)), John C. Lieske(Mayo Clinic), David J. Sas(Mayo Clinic), Georges Deschênes(Hôpital Robert-Debré), Michael J. Koren(Jacksonville Center for Clinical Research), Hadas Shasha‐Lavsky(Université Claude Bernard Lyon 1), John M. Gansner(Brigham and Women's Hospital), Wesley Hayes(Great Ormond Street Hospital), Daniel G. Fuster(University Hospital of Bern), Anne‐Laure Sellier‐Leclerc(Hôpital Femme Mère Enfant), Eva Šimková(Université Claude Bernard Lyon 1), Kenji Fujita(Alnylam Pharmaceuticals (United States)), Jeffrey M. Saland(Université Claude Bernard Lyon 1), Yaacov Frishberg(Shaare Zedek Medical Center), Sander F. Garrelfs(Emma Kinderziekenhuis), Daniella Magen(Université Claude Bernard Lyon 1), Taylor Ngo(Boehringer Ingelheim (Germany)), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), Martin Coenen, Sally‐Anne Hulton(Birmingham Children's Hospital), Tracy L. McGregor(Université Claude Bernard Lyon 1), Jaap W. Groothoff(University of Amsterdam), J. Scott Overcash(Precision Research Institute), Kristin Meliambro(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
2007 Guideline for the Management of Ureteral Calculi
|European Urology|2007|1.1k
2007 Guideline for the Management of Ureteral Calculi
|The Journal of Urology|2007|837